Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes
Authors Israel MK, Istvan E, Baron MA
Published 5 December 2008 Volume 2008:4(6) Pages 1167—1178
Marc K Israel1, Eva Istvan2, Michelle A Baron1,3
1Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; 2Novartis AG, Basel, Switzerland; 3Sanofi-Aventis, Bridgewater, New Jersey, USA
Abstract: The increasing prevalence of type 2 diabetes provides impetus for both development of new drugs to improve glycemic control and for reconsideration of treatment strategies with existing agents. Combination therapy with complementary drug classes that act on different aspects of glycemic control has been a particularly effective strategy. This work reviews the published literature reporting efficacy and safety/tolerability of nateglinide, a rapid-onset insulinotropic agent with a predominant effect to reduce postprandial glucose, when combined with metformin, a first-line agent that suppresses hepatic glucose production and thereby reduces fasting plasma glucose. The nateglinide/metformin combination has consistently been found to be both efficacious and well tolerated, whether given as initial combination therapy in drug-naïve patients or when added to metformin monotherapy. Maximum efficacy (Δ glycosylated hemoglobin [HbA1c] = –1.4% to –1.9%, sustained for up to 2 years of treatment) was seen in studies of drug-naïve patients in whom pharmacotherapy was initiated with the combination of nateglinide and metformin, and modest reductions in HbA1c (Δ = –0.5% to –1.2%, sustained for up to 24 weeks) were found when nateglinide was added to ongoing metformin monotherapy.
Conclusion: The combination of nateglinide and metformin provides a sustained degree of glycemic control not achievable with either agent given as monotherapy.
Keywords: metformin, nateglinide, combination therapy, type 2 diabetes, postprandial hyperglycemia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]